EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B

Miwa Okamoto, Rika Kurino, Ryu Miura iD, Kenzo Takada

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0285672 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Miwa Okamoto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sapporo Laboratory, EVEC, Inc., Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human cytomegalovirus causes severe diseases in children (by congenital infection) and immunocompromised patients. Treatment with antiviral agents, such as ganciclovir, is limited by their toxicity. In this study, we investigated the effectiveness of a fully human neutralizing monoclonal antibody to inhibit human cytomegalovirus infection and viral cell-to-cell spread. We isolated a potent neutralizing antibody, EV2038 (IgG1 lambda), targeting human cytomegalovirus glycoprotein B using Epstein-Barr virus transformation. This antibody inhibited human cytomegalovirus infection by all four laboratory strains and 42 Japanese clinical isolates, including ganciclovir-resistant isolates, with a 50% inhibitory concentration (IC 50 ) ranging from 0.013 to 0.105 μg/mL, and 90% inhibitory concentration (IC 90 ) ranging from 0.208 to 1.026 μg/mL, in both human embryonic lung fibroblasts (MRC-5) and human retinal pigment epithelial (ARPE-19) cells. Additionally, EV2038 prevented cell-to-cell spread of eight clinical viral isolates, with IC 50 values ranging from 1.0 to 3.1 μg/mL, and IC 90 values ranging from 13 to 19 μg/mL, in ARPE-19 cells. EV2038 recognized three discontinuous sequences on antigenic domain 1 of glycoprotein B (amino acids 549–560, 569–576, and 625–632), which were highly conserved among 71 clinical isolates from Japan and the United States. Pharmacokinetics study in cynomolgus monkeys suggested the potential efficacy of EV2038 in vivo , the concentration of which in serum remained higher than the IC 90 values of cell-to-cell spread until 28 days after intravenous injection of 10 mg/kg EV2038. Our data strongly support EV2038 as a promising candidate and novel alternative for the treatment of human cytomegalovirus infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsEpstein-Barr Virus InfectionsChildHumansEpitopesAntibodies, ViralAntibodies, MonoclonalHerpesvirus 4, HumanViral Envelope ProteinsAntibodies, NeutralizingGanciclovir

Substanzen

glycoprotein B, SimplexvirusEpitopesAntibodies, ViralAntibodies, MonoclonalViral Envelope ProteinsAntibodies, NeutralizingGanciclovir

Autor:innen und Institutionen

  • Sapporo Laboratory, EVEC, Inc., Sapporo, Hokkaido, Japan.

ORCID-Profile: Ryu Miura

Zitieren

APA

Okamoto, M., Kurino, R., Miura, R., & Takada, K. (2023). A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B. PLOS ONE. https://doi.org/10.1371/journal.pone.0285672

Vancouver

Okamoto M, Kurino R, Miura R, Takada K. A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B. PLOS ONE. 2023. doi:10.1371/journal.pone.0285672

BibTeX
@article{Okamoto2023,
  author = {Okamoto, Miwa and Kurino, Rika and Miura, Ryu and Takada, Kenzo},
  title = {A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0285672}
}
Kostenlos starten →